Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Blueprint Medicines Corporation - Common Stock (NQ:BPMC)

98.60 -0.16 (-0.16%)
Streaming Delayed Price Updated: 3:18 PM EDT, May 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Blueprint Medicines Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
ETF Returns: Mid-Cap Winners And Losers
We performed a screening of mid-cap ETFs - defined as having Assets Under Management (AUM) between $2 billion and $10 billion - to determine what funds had the largest positive and negative returns on... 
Via Benzinga
What Will AbbVie Buy Next?
Two mid-cap drugmakers stand out as logical targets for AbbVie. 
Via The Motley Fool
Analyst Expectations for Blueprint Medicines's Future
Via Benzinga
3 Small-Cap Drug Stocks to Watch as Their Clinical Trials End Soon
These three small cap drug companies could become gold or lead depending on the outcomes of their clinical trials. 
Via InvestorPlace
EPAM Systems, Amyris, Blueprint Medicines And Other Big Stocks Moving Lower On Monday
U.S. stocks traded mixed, with the Dow Jones dropping around 100 points on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
FDA OKs Blueprint Medicines' Blood Disorder Drug As First Treatment For SM Patients
The U.S. 
Via Benzinga
Analyst Expectations for Blueprint Medicines's Future
Via Benzinga
Blueprint Medicines's Return On Capital Employed Overview
Via Benzinga
Why Amedisys Shares Are Trading Higher By 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Sono Group N.V. (NYSE: SEV) shares surged 152.7% to $0.4367. Sono Group applied to Insolvency Court of Munich, Germany, to permit opening of self-administration proceeding. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 5, 2023
Via Benzinga
Analyst Ratings for Blueprint Medicines
Via Benzinga
Where Blueprint Medicines Stands With Analysts
Via Benzinga
16 Analysts Have This to Say About Blueprint Medicines
Via Benzinga
US Stocks Mixed; SAIC Posts Upbeat Results
U.S. stocks traded mixed this morning, with Dow Jones dropping around 20 points on Monday. Following the market opening Monday, the Dow traded down 0.06% to 33,740.98 while the NASDAQ rose 0.08% to... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Meta Platforms To Rally Around 30%? Here Are 10 Other Analyst Forecasts For Monday
BMO Capital boosted the price target for Equity Residential (NYSE: EQR) from $60 to $64. BMO Capital analyst John Kim upgraded the stock from Underperform to Market Perform. Equity Residential shares... 
Via Benzinga
This Biotech Could Soon Go Parabolic, But Should You Buy It?
Its situation is neither as good nor as bad as it might seem at first glance. 
Via The Motley Fool
FDA Removes Partial Clinical Hold From Blueprint Medicines' Cancer Study
Via Benzinga
Where Blueprint Medicines Stands With Analysts
Via Benzinga
Earnings Scheduled For February 16, 2023
Companies Reporting Before The Bell • RELX (NYSE:RELX) is estimated to report earnings for its Fiscal Year 2022. • Coca-Cola Europacific (NASDAQ:CCEP) is expected to report earnings for its Fiscal Year... 
Via Benzinga
Earnings Preview For Blueprint Medicines
Via Benzinga
Analyst Ratings for Blueprint Medicines
Via Benzinga
Blueprint Medicines Earns Higher Price Targets Post FDA Approval: Analysts Optimistic on Ayvakit's Future
Shares of Blueprint Medicines Corporation (NASDAQ: BPMC) after it received FDA approval for its Ayvakit (avapritinib) as the first, only treatment for  
Via Benzinga
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy. 
Via InvestorPlace
Blueprint Medicines Highlights Detailed Data From Lead Product In Blood Cancer Patients
Via Benzinga
Roche Decides To Terminate Cancer Treatment Pact With Blueprint Medicines
Via Benzinga
Where Blueprint Medicines Stands With Analysts
Via Benzinga
FDA Slaps Partial Clinical Hold On Blueprint Medicines' Early-Stage Solid Tumor Study
Via Benzinga
Blueprint Medicines's Return On Capital Employed Overview
According to data from Benzinga Pro, during Q3, Blueprint Medicines's (NASDAQ:BPMC) reported sales totaled $65.98 million. Despite a 16.62% increase in earnings, the company posted a loss of $133.16... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.